Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

AnGes (AMGXF) Stock Price & Analysis

6 Followers

AMGXF Stock Chart & Stats

$0.36$0.00(0.00%)
At close: 4:00 PM EST
$0.35$0.4$0.45$0.5Sep 18Oct 23Dec 5
Day’s Range
$0.32 - $0.40
52-Week Range
$0.32 - $0.40
Previous Close
$0.36
Volume
N/A
Average Volume (3M)
0
Market Cap
$67.46M
Enterprise Value
$19.10B
Total Cash (Recent Filing)
$296.72M
Total Debt (Recent Filing)
$723.78M
Price to Earnings (P/E)
―
Beta
-0.33
Next Earnings
Feb 05, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Accelerating revenue indicates improving commercialization activity for AnGes and provides a stronger base from which to develop its biotechnology portfolio. If this trend persists, greater product or collaboration income could improve operating leverage and support progress toward sustainable scale.

Low Leverage

Low leverage gives AnGes more financial flexibility than a heavily indebted biotechnology company, because fewer resources are committed to debt service. This can preserve room to fund research, regulatory work, and commercialization while reducing balance-sheet pressure during development cycles.

Multiple Monetization Routes

AnGes has several potential ways to monetize its gene-based medicine pipeline rather than relying solely on direct product sales. Licensing, milestones, royalties, and funded development work can diversify future revenue sources and create commercial options as programs advance.

Bears Say

Persistent Losses

Persistent operating and net losses show that the business has not yet established sustainable earnings, despite stronger revenue. Continued losses can limit internal reinvestment, increase dependence on financing, and make future performance highly dependent on successful commercialization of its pipeline.

Ongoing Cash Burn

Deeply negative operating and free cash flow indicate that AnGes is consuming cash to sustain its operations rather than funding them internally. This creates ongoing reliance on external funding or existing balance-sheet resources and may constrain research and commercialization capacity.

Balance-Sheet Erosion

Declining equity and assets indicate that continuing losses and cash usage are reducing the company’s financial base over time. Even with low leverage, this erosion can weaken resilience, narrow funding flexibility, and increase the importance of achieving profitability or securing additional capital.

AMGXF FAQ

What was AnGes’s price range in the past 12 months?
AnGes lowest stock price was $0.32 and its highest was $0.40 in the past 12 months.
What is AnGes’s market cap?
AnGes’s market cap is $67.46M.
When is AnGes’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were AnGes’s earnings last quarter?
AnGes released its earnings results on Aug 07, 2026. The company reported -$0.026 earnings per share for the quarter.
Is AnGes overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does AnGes pay dividends?
AnGes does not currently pay dividends.
What is AnGes’s EPS estimate?
AnGes’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AnGes have?
AnGes has 412,305,150 shares outstanding.
What happened to AnGes’s price movement after its last earnings report?
AnGes reported an EPS of -$0.026 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of AnGes?
Currently, no hedge funds are holding shares in AMGXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology